Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

Phase 1

Terminated

Conditions: Childhood Central Nervous System Mixed Germ Cell Tumor
Childhood Infratentorial Ependymoma
Childhood Supratentorial Ependymoma
Recurrent Childhood Large Cell Lymphoma
Recurrent Childhood Subependymal Giant Cell Astrocytoma
Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Recurrent Childhood Visual Pathway Glioma
Childhood Atypical Teratoid/Rhabdoid Tumor
Childhood Choroid Plexus Tumor
Pituitary Eosinophilic Adenoma

Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Other: diagnostic laboratory biomarker analysis
Other: pharmacological study
Drug: dexamethasone

First Posted Date: 2010-03-17

Last Posted Date: 2014-11-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 129

Registration Number: NCT01088763

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States
🇺🇸
Indiana University Medical Center, Indianapolis, Indiana, United States

and more 9 locations

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Phase 1

Completed

Conditions: Hematological Malignancy

Interventions: Drug: Isatuximab SAR650984
Drug: Dexamethasone

First Posted Date: 2010-03-10

Last Posted Date: 2024-11-01

Lead Sponsor: Sanofi

Target Recruit Count: 351

Registration Number: NCT01084252

Locations: 🇪🇸
Investigational Site Number : 724008, Sevilla, Spain
🇹🇷
Investigational Site Number : 792002, Ankara, Turkey
🇹🇷
Investigational Site Number : 792005, Ankara, Turkey

and more 56 locations

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma

Phase 2

Completed

Conditions: Relapsed and Bortezomib Refractory Multiple Myeloma
Refractory Multiple Myeloma
Multiple Myeloma in Relapse

Interventions: Drug: panobinostat
Drug: bortezomib
Drug: dexamethasone

First Posted Date: 2010-03-10

Last Posted Date: 2017-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 55

Registration Number: NCT01083602

Locations: 🇺🇸
Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst., Atlanta, Georgia, United States
🇺🇸
Duke University Medical Center Dept. of DUMC (4), Durham, North Carolina, United States
🇺🇸
MD Anderson Cancer Center/University of Texas MD Anderson CC, Houston, Texas, United States

and more 10 locations

The Efficacy of Topical Minocycline in Managing Symptomatic Oral Lichen Planus

Phase 3

Conditions: Oral Lichen Planus

Interventions: Drug: Dexamethasone
Drug: Minocycline

First Posted Date: 2010-03-09

Last Posted Date: 2010-03-09

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 30

Registration Number: NCT01083420

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Phase 2

Completed

Conditions: Amyloidosis

Interventions: Drug: Bortezomib
Drug: Dexamethasone
Drug: Melphalan

First Posted Date: 2010-03-09

Last Posted Date: 2020-09-25

Lead Sponsor: Boston Medical Center

Target Recruit Count: 35

Registration Number: NCT01083316

Locations: 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

Phase 3

Completed

Conditions: Relapsed Multiple Myeloma

Interventions: Drug: Dexamethasone
Drug: Lenalidomide
Drug: Carfilzomib

First Posted Date: 2010-03-04

Last Posted Date: 2022-09-21

Lead Sponsor: Amgen

Target Recruit Count: 792

Registration Number: NCT01080391

Locations: 🇺🇸
Providence St. Joseph Medical Center, Burbank, California, United States
🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
Weill Cornell Medical College, New York, New York, United States

and more 123 locations

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

Phase 1

Terminated

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: pomalidomide
Drug: dexamethasone
Drug: rituximab

First Posted Date: 2010-03-02

Last Posted Date: 2016-07-25

Lead Sponsor: Steven P. Treon, MD, PhD

Target Recruit Count: 7

Registration Number: NCT01078974

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant

Phase 2

Terminated

Conditions: Refractory Multiple Myeloma

Interventions: Drug: liposomal doxorubicin
Drug: bortezomib
Drug: dexamethasone
Drug: cyclophosphamide

First Posted Date: 2010-03-02

Last Posted Date: 2015-01-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT01078441

Locations: 🇺🇸
Graham Hospital Association, Canton, Illinois, United States
🇺🇸
Mason District Hospital, Havana, Illinois, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

and more 127 locations

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

Phase 3

Completed

Conditions: Light Chain Deposition Disease
Primary Systemic Amyloidosis

Interventions: Drug: melphalan
Drug: dexamethasone
Drug: bortezomib

First Posted Date: 2010-03-02

Last Posted Date: 2022-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 11

Registration Number: NCT01078454

Locations: 🇺🇸
Illinois CancerCare-Canton, Canton, Illinois, United States
🇺🇸
Illinois CancerCare-Carthage, Carthage, Illinois, United States
🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

and more 206 locations

Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis

Phase 2

Completed

Conditions: Primary Systemic Amyloidosis

Interventions: Drug: bortezomib
Drug: cyclophosphamide
Drug: dexamethasone

First Posted Date: 2010-02-22

Last Posted Date: 2014-04-02

Lead Sponsor: Mayo Clinic

Target Recruit Count: 2

Registration Number: NCT01072773

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy